Titelangaben
Molitorisová, Alexandra ; Purnhagen, Kai ; Rostoks, Nils ; Eriksson, Dennis ; Wasmer, Martin:
Regulatory Aspects of Plants resulting from New Genomic Techniques in the EU.
In: Abd-Elsalam, Kamel ; Ahmad, Aftab
(Hrsg.):
Global Regulatory Outlook for CRISPRized Plants. -
New York
: Academic Press
,
2023
. - S. 251-279
ISBN 978-0443184451
Angaben zu Projekten
Projekttitel: |
Offizieller Projekttitel Projekt-ID Innovate Food Law PU424/2-1 Innovate Food Law FP00535 Improving adaptability and resilience of perennial ryegrass for safe and sustainable food systems through CRISPR-Cas9 technology - EditGrass4Food EEZ/BPP/VIAA/2021/4 COST Action PlantEd CA18111 |
---|---|
Projektfinanzierung: |
AM and KP are supported by Deutsche Forschungsgemeinschaft (DFG), grant agreement PU424/2-1 and by the Oberfrankenstiftung, grant agreement No. FP00535. NR was partially supported by the Baltic Research Program project EEZ/BPP/VIAA/2021/4 “Improving adaptability and resilience of perennial ryegrass for safe and sustainable food systems through CRISPR-Cas9 technology - EditGrass4Food”. NR, DE and KPP are partially supported by the COST Action PlantEd (CA18111). |
Abstract
Nobel prize-winning CRISPR/Cas gene editing technology will strengthen plant breeding in terms of efficiency and precision. The technology is based on precise site-directed alterations in plant genomes with the possibility of off-target changes greatly reduced compared to the conventionally used randomly induced mutagenesis. In the EU, the Court of Justice of the European Union adopted the reasoning that organisms obtained by novel mutagenesis techniques share a comparable risk profile as those obtained by transgenesis. Hence, EU GMO law applies to the same extent. However, it has not yet been clarified by binding legal interpretation if the EU GMO law applies to all products of new genomic techniques (NGTs), such as gene editing. Here we describe in detail the GMO regulatory system in the EU, as well as the recent developments regarding different NGT. Finally, we examine the potential solutions for the regulatory conundrum and potential impact of EU regulation on commercial development of gene-edited organisms in the EU.